Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain metastases in patient with 1-4 lesions.
Checked against the public recordLast updated Oct 6, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Stanford University
- Interventions being studied
- Drug: Vorinostat; Procedure: Radiation Therapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * All patients age 18 years and older with histologically proven non-small cell lung cancer and 1-4 brain metastases, each measuring less than 2 cm will be eligible. Prior surgery or radiation is allowed as long as the target metastatic lesion(s) has not been treated with previous radiation. * Adequate organ function (section 3.1.10). * ECOG performance status 0-2. * Life expectancy of \>=12 weeks. * Systemic chemotherapy washout period \>=7 days. Exclusion Criteria: Patients who have previously been treated with whole brain irradiation, pediatric patients (age \<18), pregnant women, and patients who are unable to give informed consent.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Stanford University School of MedicineStanford, California
- Moffitt Cancer CenterTampa, Florida
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 6, 2017. Always confirm current availability with the study team.